Barbara Handelin, PhD is cofounder and CEO of Audacity Therapeutics, a public benefit (B Corp) pharmaceutical company which is seeding a new public benefit industry, operating in green practices and delivering drugs at a cost for a sustainable healthcare economy. She is a veteran entrepreneur and molecular medical geneticist who has pioneered the responsible application of genetics and molecular innovation to clinical medicine over a 35 year career. In 1987 Dr. Handelin established the first commercial DNA testing laboratories at Integrated Genetics (later Genzyme Genetics). She also co-founded Genovo), a biosimulation company, (Kenna Technologies). and BioPontis Alliance, a novel investment fund. Dr. Handelin has served on the board of several genomics companies (EXACT, RedPath IP, Stemina BioSciences) as well as on a variety of federal committees and advisory panels on ethics in genetic testing, including the Secretary’s Advisory Panel on Genetics, Health and Society.

Sandra Heibel, PhD believes in fiscally responsible development of therapeutics to benefit the public good. As the COO for Audacity Therapeutics, she applies her multi-disciplinary expertise as a scientist, program manager, and regulatory specialist with extensive knowledge of drug development and rare disease regulatory strategy. She co-leads the Commission on Financing a Public Benefit Biotechnology Industry, an initiative to develop a finance model that can support a new way of producing more medicines for more diseases at sustainable costs. She also serves as the Chief of Science and Regulatory Affairs at Haffner Associates where she works with Dr. Marlene Haffner, the preeminent expert in orphan drug regulatory affairs. Prior to working in the regulatory affairs field, she spent 13 years conducting preclinical and clinical research in a laboratory setting with a focus on rare, heritable diseases.